Medimmune Limited

Wyeth

David C Lowe

Matthew Alexander Sleeman

Davinder Gill

Viia Valge-Archer

Geertruida Machteld Veldman

Ralph Raymond Minter

Jing Li

Lynette A Fouser

Caroline S Russell

Darren Schofield

Suzanne E Cohen

Albert George Thom

Jonathan P Hatcher

Iain Patrick Chessell

Jamie Iain Campbell

Duncan James Cochrane

Simon Charles Cruwys

Maria Anastasia Teresa Groves

Donna Kirsty Finch

Sara Carmen

Emma Suzanne Cohen

Katherine Ann Vousden

Tomas M Mustelin

David G Rees

Robin Butler

Ian C Scott

Martin D Strain

Elizabeth H England

Benjamin P Kemp

Catherine L Overed-Sayer

Kirsty Houslay

Tristan J Vaughan

Deborah A Young

Laird Bloom

James Button

Yulia Vugmeyster

Benjamin David Grimshaw

Stacey Chin

Viia Valge-archer

Davinder S Gill

Albert B Thom

This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNFα antagonist. The NGF antagonist and the TNFα antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNFα antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNFα antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNFα antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNFα antagonist administered alone.

Compounds and methods for treating pain

The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.

Polynucleotides encoding IL33 antibodies and methods of using the same

This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF&#x3b1; antagonist. The NGF antagonist and the TNF&#x3b1; antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF&#x3b1; antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF&#x3b1; antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF&#x3b1; antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF&#x3b1; antagonist administered alone.

The present invention relates to a library (in particular a phage display library) from which an improved human antibody having greater specificity and potency for its target may be generated; and to methods of generating such a human antibody. In particular, the invention relates to a human antibodies against challenging targets obtainable from such a library and which have HCDR3s of at least 18 amino acids in length.

Phage display library, members thereof and uses of the same

IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same

This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a Kof 10 pM or less when measured by Kinexa&#x2122;. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).

Antibodies to IL-1 R1 and methods of making them

Nucleic acid molecule encoding a specific IL-1R1 antibody

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

Nucleic acid encoding antibody to human IL-22

Antibodies to IL-1R1

Antibodies to human IL-22

The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

Interleukin-21 receptor binding proteins

Antibodies against human IL-22 and uses therefor

Growing community of inventors

Hertfordshire, United Kingdom

David C Lowe